United States Antimony Corporation is offering 3,500,000 shares of common stock at $7.50 per share, for gross proceeds of $26.25 million. The deal is a best-efforts placement through A.G.P./Alliance Global Partners to a single purchaser, with the placement agent earning a 7.0% cash fee, partially offset by a credit.
The company expects net proceeds of approximately $25.4 million (about $25.56 million after fees, expenses and the credit), which it plans to use for working capital, buying additional antimony and other critical mineral inventory, expanding leasehold positions, potential acquisitions of critical mineral assets or companies, and possible expansion of its Madero smelter in Mexico above its 200‑ton‑per‑month capacity.
Shares outstanding were 131,092,887 as of October 3 2025 and are expected to be 134,592,887 after the offering. The company highlights that new investors will face immediate dilution, as pro forma net tangible book value would rise to $0.78 per share versus the $7.50 offering price.
United States Antimony Corporation filed a Form 8-K to share that, on October 6, 2025, it issued a press release announcing the pricing of a registered direct offering. The company is using this current report to make the information broadly available under Regulation FD, which is designed to ensure that all investors receive important company information at the same time.
The press release, dated October 6, 2025, is included as an exhibit to the report and is incorporated by reference. The company also clarifies that this disclosure is being treated as “furnished” rather than “filed,” which limits how it is used for certain legal liability purposes under the securities laws.
United States Antimony Corp (UAMY) director and officer Lloyd Bardswich reported a sale of 40,000 shares of the company's common stock on 09/29/2025 at a price of $6.44 per share. After the sale the filing shows beneficial ownership listed as 594.047 (as reported). The Form 4 was signed by the reporting person on 10/04/2025. No derivative transactions or additional purchases were disclosed.
Jeffrey Russell Fink, an officer and director of United States Antimony Corp (UAMY), reported two open-market dispositions on 10/03/2025. The filing shows a sale of 2,833 shares at $8.16 and a sale of 8,000 shares at $8.12. After those transactions the reported beneficial ownership totals are listed as 64,000 shares and 56,000, respectively, held in a direct capacity. The Form 4 is signed by the reporting person and indicates the transactions were not reported as part of a 10b5-1 plan. The filing provides a straightforward record of insider selling activity without additional commentary or explanatory notes.
UAMY filed a Form 144 notice for proposed sales of common stock.
The notice lists 2,833 shares (aggregate market value $23,103.12) and 8,000 shares (aggregate market value $64,960.80) to be sold through Merrill Edge on NYSE American, with an approximate sale date of October 3, 2025. The seller acquired 33,333 shares via restricted stock vesting on January 29, 2025 as compensation.
United States Antimony Corp (UAMY) director Michael A. McManus Jr. reported selling 50,000 shares of common stock on 10/01/2025 at a reported price of $7.316 per share. After the sale he beneficially owns 531,965 shares. The Form 4 was signed on 10/02/2025 and shows the transaction as a direct disposition by a director.
United States Antimony Corp (UAMY) filed a Form 144 disclosing a proposed sale of 50,000 common shares with an aggregate market value of $350,000. The filing states the shares represent part of the company's outstanding 120,723,320 shares and that the approximate sale date is 10/01/2025 through the NYSE via Merrill Lynch. The shares were acquired on 05/15/2024 as a stock bonus from US Antimony Corp, and no sales by the same person were reported in the past three months. The filer certifies they are unaware of any undisclosed material adverse information about the issuer.
United States Antimony Corp (UAMY) filed a Form 144 reporting a proposed sale of 12,500 common shares through Merrill EDGE (Jacksonville, FL) on the NYSE American with an approximate aggregate market value of $98,375. The shares were acquired on 01/29/2025 as restricted stock vesting from the issuer, totaling 33,333 shares received on that date and paid as compensation. The filer reports 120,723,320 shares outstanding and lists an approximate sale date of 09/24/2025. The filing states there were no securities sold in the past three months by the selling person and includes the standard representation that the seller is not aware of undisclosed material adverse information.
Form 144 filed for United States Antimony Corp (UAMY) reporting a proposed sale of 40,000 common shares with an aggregate market value of $245,000, listed for an approximate sale date of 09/29/2025 on NYSE American through broker Canaccord Genuity.
The filing shows the shares were originally acquired in open-market cash purchases on 08/18/2022 and 08/19/2022 in four lots totaling the 40,000 shares, with payment settled in cash. The issuer has 120,723,320 shares outstanding. The filer reports no sales of these securities in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.
Jeffrey R. Fink, an officer and director of United States Antimony Corp (UAMY), reported the sale of 12,500 shares of the company's common stock on September 24, 2025 at a reported price of $7.87 per share. After the transaction he beneficially owned 66,833 shares. The Form 4 was signed on October 2, 2025. The filing discloses a straightforward open-market disposition by an insider and contains no derivative transactions or additional explanations.